KMT2A and leukemia: WP1130 treatment significantly prolonged the overall survival in primary MLL-AF9-transduced leukemia mice (Fig. 6h, median survival of WP1130 versus vehicle, 65 days versus 49.5 days, respectively; P < 0.001).